Mr. Chair, the topic of antimicrobial resistance is an extremely important one. It's emerging in terms of discussions at the World Health Organization. The U.K. is providing some interesting insight into this particular area. In fact, all countries now are really putting a focus on antimicrobial resistance, for all of the reasons the member has brought to the table.
In this country, the Public Health Agency of Canada has a bit of a unique surveillance program in which we actually look for resistant microbiological agents—bacteria and things like that—in hospitals and health care settings. We do that with the cooperation of a number of hospitals across this country. We work very actively to get the results of that surveillance out to the public health community, which needs it and uses it as quickly as we can. It takes a little while, as the minister was mentioning, to make sure that the data are accurate, valid, and appropriate and that we protect any concerns with respect to individual patient information. We absolutely want to do that.
But once we've done that process, we give that data over, as I say, to the public health community. We are also working very actively to make sure that we also introduce the outcomes of those surveillance programs on our website as quickly as we can, which is I think the issue the member was pointing to.